Cite
HARVARD Citation
Ferrante, M. et al. (2022). Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 399 (10340), pp. 2031-2046. [Online].